Panobinostat
As of the edition of 20 October 2026, Panobinostat is a small molecule: marketed, first approved in 2015 (US); US protection ends in 2028.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Small molecule
- Brand name
- Farydak
- First approved
- 23 February 2015 (US)
- Approvals on record
- 5 in 3 regions
- Holder of the most recent approval
- pharmaand; 3 holders in all
- Registered trials
- 143, 50 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Skin and connective tissue; Urinary and reproductive
US protection
US protection ends in 2028.
The last listed US drug-substance patent ends in 2028. The application that gives this date is held by Secura Bio.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product3 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 3 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 0 | 0 |
| Phase 1 | 59 | 36 | 1 | 18 |
| Phase 2 | 77 | 41 | 1 | 31 |
| Phase 3 | 3 | 2 | 0 | 1 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 143 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novartis | Originator and Lead sponsor of trials | 2006 to now |
| pharmaand | Applicant and Lead sponsor of trials | 2015 to now |
| Secura Bio | Acquired holder | 2019 to now |